Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Shares Repurchased (2017 - 2020)

Ligand Pharmaceuticals (LGNDZ) has disclosed Shares Repurchased for 8 consecutive years, with $4.7 million as the latest value for Q4 2020.

  • Quarterly Shares Repurchased fell 94.25% to $4.7 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Sep 2021, down 96.97% year-over-year, with the annual reading at $15.0 million for FY2025, N/A changed from the prior year.
  • Shares Repurchased hit $4.7 million in Q4 2020 for Ligand Pharmaceuticals, down from $73.3 million in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $181.2 million in Q3 2019 to a low of $502000.0 in Q1 2016.
  • Historically, Shares Repurchased has averaged $59.7 million across 5 years, with a median of $50.8 million in 2018.
  • Biggest five-year swings in Shares Repurchased: skyrocketed 7899.21% in 2019 and later plummeted 94.25% in 2020.
  • Year by year, Shares Repurchased stood at $502000.0 in 2016, then surged by 291.63% to $2.0 million in 2017, then surged by 3467.7% to $70.1 million in 2018, then grew by 16.82% to $81.9 million in 2019, then tumbled by 94.25% to $4.7 million in 2020.
  • Business Quant data shows Shares Repurchased for LGNDZ at $4.7 million in Q4 2020, $73.3 million in Q1 2020, and $81.9 million in Q4 2019.